There is evidence that 5-LOX, 15-LOX, and, to a lesser extent, 12-LOX are promising pharmacological targets for the therapy of OA and RA due to their involvement in the inflammatory process leading to degenerative joint diseases [90,91]. This evidence concerns the gene ALOX5 and rheumatoid arthritis.